ALK and non-small cell lung carcinoma: Brigatinib was approved in South Korea in November 2018 (and received reimbursement on 1 April 2019) for the second‐line treatment of patients with locally advanced or metastatic ALK+ NSCLC who have progressed on crizotinib.